Panel
Over twenty-one years’ experience in Cell and Gene Therapy (CGT) and the technology involved in the processing and manufacturing.
Eighteen years at Miltenyi Biotec, initially running their bone marrow transplant and cell therapy business, technically and commercially. Looking back, this means playing a very small part in progressing products and processes in the clinic that have now had companies grow up around them, such as Autolus, Adaptimmune, Orchard, Quell, Resolution and more.
Going on to run Miltenyi’s strategic partnerships with such partners as Autolus and GSK. Central to the Prodigy launch and Miltenyi’s widening cell therapy and analytics portfolios and placing them in the industry, actually selling and placing the first Prodigys in the field and part of the first clinical use of the Prodigy for CAR T manufacturing, thus leading Miltenyi’s way into acadaemia, the clinic and bioindustry.
Going on to gain deep experience as a founding member of Ori Biotech (and first employee) as their Chief Business Officer, developing a purpose-built manufacturing cell processing technology more amenable to scale. Experience in building a technology, building a company, building partnerships and collaborations and supporting investor interest and a total of $150M raised.
A long road in cell and gene therapy manufacturing that now seems always to have been leading to Cellular Origins. As Head of Global Business Development and Marketing at Cellular Origins, personal passions and vision are aligned in making a difference and dragging manufacturing technology by the ears up to where it needs to be and to put real substance and realisation to the word that is too often said but seldom meant, ‘Automation’, now full automation and bringing robotics to our maturing industry. Developing and maintaining current partnerships, discovering and securing new partnerships and progressing key industry collaborations with other technology providers, as manufacturing advanced therapies at scale is a challenge that can only be surmounted with in partnership. To best place Cellular Origins to disrupt and evolve CGT manufacturing and to bridge the gap between the need and the ability to scale and to make a positive difference to the lives of as many patients as can benefit from the promise of CGT.
What does your role at BIA involve?
Rosie leads the BIA’s policy work on access to medicines, rare diseases, cell and gene therapies and antimicrobial resistance. This involves providing the secretariat for the BIA’s Cell and Gene Therapy Advisory Committee (CGTAC) and Rare Disease Industry Group (RDIG). She is also responsible for organising the BIA’s annual Parliament Day, which brings CEOs and senior representatives from BIA member companies to Westminster to meet with politicians and policymakers.
Previous experience
Previously, Rosie worked as a Senior Research Consultant at a Westminster-based public affairs agency, where she supported clients from a range of sectors, including pharmaceuticals, technology and financial services. Prior to that, Rosie worked as a Management Consultant at KPMG, where she assisted on financial and regulatory projects with large corporate clients. She has a BA in Human, Social and Political Sciences from the University of Cambridge.
